Effect of Low-dose (1mg/day) "Pitavastatin" on Left Ventricular Diastolic Function and Albuminuria in Patients with Hyperlipidemia
Effect of Low-dose (1mg/day) "Pitavastatin" on Left Ventricular Diastolic Function and Albuminuria in Patients with Hyperlipidemia
复制标题
小剂量（1mg/天）“匹伐他汀”对高脂血症患者左心室舒张功能和蛋白尿的影响
DOI：
10.1016/j.amjcard.2011.01.054
复制
发表时间：
2011
期刊：
影响因子：
2.8
通讯作者：
赤池雅史
中科院分区：
文献类型：
--
作者：
野間玄督;東幸仁;赤池雅史
本研究的目的是评估调节他汀类药物对心肾功能的保护作用的因素，而不考虑其降脂作用。为了治疗血脂异常，对65例高脂血症患者给予低剂量匹伐他汀（1.0 mg/天）。排除标准包括左心室射血分数<40%和明显的肾脏疾病。年龄和性别匹配的高脂血症患者（n = 40）作为对照。匹伐他汀治疗12 ~ 16周后，（从143.5 ± 31.4到98.2 ± 19.4 mg/dl，p <0.01），甘油三酯（157.7 ± 57.2 ~ 140.5 ± 60.7 mg/dl，p <0.01），E/e′（10.8 ± 6.2 ~ 9.0 ± 4.5，p <0.05），左室舒张功能指标，尿蛋白（从47.6 ± 55.9至28.5 ± 40.0 mg/g肌酐，p <0.01）。此外，匹伐他汀降低血清转化生长因子-β1（709 ± 242）~（550 ± 299）pg/ml，P <0.01（从6.6 ± 4.1到5.0 ± 3.1 μg/g肌酐，p <0.01），氧化应激标志物，尿硝酸盐和亚硝酸盐含量从22.5 ± 14.6增加到29.4 ± 27.6nmol/g肌酐（P <0.05）。在对照组中未观察到此类变化。多元回归分析显示匹伐他汀对心肾功能的影响与抑制氧化应激有关，但与降低低密度脂蛋白胆固醇无关。总之，匹伐他汀降低E/e′和白蛋白尿，这与抑制氧化应激有关。
The aim of the present study was to evaluate the factors that modulate the protective action of statins on cardiorenal function, regardless of the lipid-lowering effect. To treat abnormal serum lipid profiles, low-dose pitavastatin (1.0 mg/day) was administered to 65 hyperlipidemic patients. The exclusion criteria included left ventricular ejection fraction <40% and apparent renal disease. Age- and gender-matched patients with hyperlipidemia (n = 40) served as the controls. After 12 to 16 weeks of pitavastatin treatment, pitavastatin had decreased low-density lipoprotein cholesterol (from 143.5 ± 31.4 to 98.2 ± 19.4 mg/dl, p <0.01), triglycerides (from 157.7 ± 57.2 to 140.5 ± 60.7 mg/dl, p <0.01), E/e′ (from 10.8 ± 6.2 to 9.0 ± 4.5, p <0.05), a parameter of left ventricular diastolic function, and albuminuria (from 47.6 ± 55.9 to 28.5 ± 40.0 mg/g creatinine, p <0.01). Furthermore, pitavastatin decreased serum transforming growth factor-β1 (from 709 ± 242 to 550 ± 299 pg/ml, p <0.01), urinary 8-hydroxy-2′-deoxyguanosine (from 6.6 ± 4.1 to 5.0 ± 3.1 μg/g creatinine, p <0.01), an oxidative stress marker, and increased urinary nitrate and nitrite (from 22.5 ± 14.6 to 29.4 ± 27.6 nmol/g creatinine, p <0.05). No such changes were observed in the controls. Multiple regression analysis in the pitavastatin group revealed the effect of pitavastatin on cardiorenal function was associated with suppression of oxidative stress, but not on low-density lipoprotein cholesterol reduction. In conclusion, pitavastatin decreases E/e′ and albuminuria, which is associated with suppression of oxidative stress.